Differentiation of human induced pluripotent stem cells into cardiac valve cells using 2D and 3D differentiation protocols.

IF 7.8 2区 医学 Q1 CELL & TISSUE ENGINEERING
Z Farzaneh, A Brückner, B K Fleischmann, S Rieck
{"title":"Differentiation of human induced pluripotent stem cells into cardiac valve cells using 2D and 3D differentiation protocols.","authors":"Z Farzaneh, A Brückner, B K Fleischmann, S Rieck","doi":"10.1186/s13287-026-05132-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Given the high relevance of human cardiac valve disease, recent research aims to differentiate human induced pluripotent stem cells (hiPSCs) into valve endothelial-like cells (VELCs) and, through endothelial-to-mesenchymal transition (EndMT), into valve interstitial-like cells (VILCs).</p><p><strong>Methods: </strong>Here, we modified a 2D differentiation protocol demonstrating that VEGF can serve as the sole driver for differentiating cardiac progenitor cells (CPCs) into VELCs. Next, we utilized the so-called GiWi protocol (inhibition of glycogen synthase kinase, followed by inhibition of the Wnt pathway) to derive VELCs from 3D endocardial spheres. To this aim, hiPSCs were first differentiated into cardiac progenitor (CP) spheres using CHIR99021 (12 µM) and IWP2 (5 µM). Subsequent treatment with E8 medium containing high-dose FGF2 (100 ng/ml) resulted in endocardial spheres enriched for VELCs. For EndMT induction, endocardial spheres were MACS-sorted for PECAM1<sup>+</sup> VELCs and transdifferentiated into ACTA2<sup>+</sup>/CDH5<sup>-</sup> VILCs using TGFβ1 (200 ng/ml).</p><p><strong>Results: </strong>Using VEGF as main driver to differentiate CPCs into VELCs in 2D, the generated VELCs appeared stable over time, can be maintained in vitro and transdifferentiated into ACTA2<sup>+</sup> VILCs using FGF2 (100 ng/ml) and TGFβ1 (50 ng/ml). Besides, our novel 3D differentiation protocol yielded endocardial spheres, which were highly enriched with VELCs, as shown by the expression of GATA4 (≈ 83%), PECAM1 (≈ 69%), and nuclear NFATC1 (≈ 76%), along with typical functional characteristics such as network formation, LDL uptake and the ability to undergo EndMT.</p><p><strong>Conclusions: </strong>Overall, we developed a 2D differentiation protocol that produces stable VELCs and a high percentage of VILCs upon EndMT induction. We also established a new, efficient, and cost-effective protocol for the 3D differentiation of endocardial spheres to better mimic a physiologically relevant environment, thereby enabling improved maturation.</p>","PeriodicalId":21876,"journal":{"name":"Stem Cell Research & Therapy","volume":"17 1","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13330356/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem Cell Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13287-026-05132-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Given the high relevance of human cardiac valve disease, recent research aims to differentiate human induced pluripotent stem cells (hiPSCs) into valve endothelial-like cells (VELCs) and, through endothelial-to-mesenchymal transition (EndMT), into valve interstitial-like cells (VILCs).

Methods: Here, we modified a 2D differentiation protocol demonstrating that VEGF can serve as the sole driver for differentiating cardiac progenitor cells (CPCs) into VELCs. Next, we utilized the so-called GiWi protocol (inhibition of glycogen synthase kinase, followed by inhibition of the Wnt pathway) to derive VELCs from 3D endocardial spheres. To this aim, hiPSCs were first differentiated into cardiac progenitor (CP) spheres using CHIR99021 (12 µM) and IWP2 (5 µM). Subsequent treatment with E8 medium containing high-dose FGF2 (100 ng/ml) resulted in endocardial spheres enriched for VELCs. For EndMT induction, endocardial spheres were MACS-sorted for PECAM1+ VELCs and transdifferentiated into ACTA2+/CDH5- VILCs using TGFβ1 (200 ng/ml).

Results: Using VEGF as main driver to differentiate CPCs into VELCs in 2D, the generated VELCs appeared stable over time, can be maintained in vitro and transdifferentiated into ACTA2+ VILCs using FGF2 (100 ng/ml) and TGFβ1 (50 ng/ml). Besides, our novel 3D differentiation protocol yielded endocardial spheres, which were highly enriched with VELCs, as shown by the expression of GATA4 (≈ 83%), PECAM1 (≈ 69%), and nuclear NFATC1 (≈ 76%), along with typical functional characteristics such as network formation, LDL uptake and the ability to undergo EndMT.

Conclusions: Overall, we developed a 2D differentiation protocol that produces stable VELCs and a high percentage of VILCs upon EndMT induction. We also established a new, efficient, and cost-effective protocol for the 3D differentiation of endocardial spheres to better mimic a physiologically relevant environment, thereby enabling improved maturation.

利用2D和3D分化方案将人诱导多能干细胞分化为心脏瓣膜细胞。
背景:鉴于人类心脏瓣膜疾病的高度相关性,最近的研究旨在将人诱导多能干细胞(hiPSCs)分化为瓣膜内皮样细胞(VELCs),并通过内皮-间充质转化(EndMT)转化为瓣膜间质样细胞(VILCs)。方法:在这里,我们修改了2D分化方案,证明VEGF可以作为心脏祖细胞(CPCs)分化为VELCs的唯一驱动因素。接下来,我们利用所谓的GiWi方案(抑制糖原合成酶激酶,然后抑制Wnt途径)从三维心内膜球中获得velc。为此,首先使用CHIR99021(12µM)和IWP2(5µM)将hiPSCs分化为心脏祖细胞(CP)球。随后用含有高剂量FGF2 (100 ng/ml)的E8培养基处理,可产生富含velc的心内膜球。对于EndMT诱导,心内膜球经macs筛选为PECAM1+ velc,并使用tgf - β1 (200 ng/ml)转分化为ACTA2+/CDH5- vilc。结果:在2D中以VEGF为主要驱动因子诱导CPCs向VELCs分化,生成的VELCs随着时间的推移呈现稳定状态,可在体外维持,并在FGF2 (100 ng/ml)和TGFβ1 (50 ng/ml)作用下转分化为ACTA2+ VILCs。此外,我们的新3D分化方案产生了富含velc的心内膜球,如GATA4(≈83%)、PECAM1(≈69%)和核NFATC1(≈76%)的表达,以及典型的功能特征,如网络形成、LDL摄取和EndMT的能力。结论:总的来说,我们开发了一种2D分化方案,在EndMT诱导下产生稳定的velc和高百分比的vilc。我们还建立了一种新的、高效的、具有成本效益的心内膜球三维分化方案,以更好地模拟生理相关环境,从而促进成熟。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Stem Cell Research & Therapy
Stem Cell Research & Therapy CELL BIOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
13.20
自引率
8.00%
发文量
525
审稿时长
1 months
期刊介绍: Stem Cell Research & Therapy serves as a leading platform for translational research in stem cell therapies. This international, peer-reviewed journal publishes high-quality open-access research articles, with a focus on basic, translational, and clinical research in stem cell therapeutics and regenerative therapies. Coverage includes animal models and clinical trials. Additionally, the journal offers reviews, viewpoints, commentaries, and reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书